HM17321

HM17321 is a novel, long-acting peptide-based analog of urocortin-2 (UCN2) that selectively targets the corticotropin-releasing factor 2 receptor (CRF2 receptor). Developed by Hanmi Pharmaceutical using advanced AI and structural modeling technologies, it is designed for high-quality obesity management. Unlike GLP-1-based therapies—which often result in significant muscle loss during weight reduction—HM17321 reduces fat mass while simultaneously increasing lean muscle mass and improving muscle function. Preclinical studies have demonstrated its ability to promote favorable body recomposition, making it a promising candidate for both monotherapy and combination therapy with incretin drugs to enhance weight loss quality and preserve muscle[1][5][6][8].

Other names

LA-UCN2LA-UCN-2LA-UCN 2